Ulotaront (SEP-363856) is a Phase III candidate with FDA Breakthrough Therapy Designation for the treatment of schizophrenia with demonstrated efficacy based on a physician-rated scale (PANSS) in a 4-week placebo-controlled trial and continued improvement in an open-label extension study. Reviewer Jake Schwarz says, “ulotaront was developed [...]
1 minute read
Jan. 17, 2022
Ulotaront: a TAAR1 GPCR Agonist with 5-HT1A Receptor Activity for Schizophrenia
ulotaront
TAAR1 GPCR agonist phase III candidate for schizophrenia from in vivo phenotypic screening ACS Medicinal Chemistry Letters Sunovion Pharmaceuticals, Marlborough, MA
Reviewer: